FEHB GLP-1 Coverage: Why Wegovy Costs $420 or $9,840

Last Updated: May 31, 2026 Reading Time: 9 min

Every FEHB plan now has to cover at least one GLP-1 weight-loss drug. That sounds like good news until you see the bill. The exact same Wegovy prescription can cost a federal employee about $420 a year on one plan and nearly $9,840 a year on another. The drug is identical. The only variable is which plan you picked at Open Season. Here's the coverage map, the diabetes-versus-weight-loss trap most people get wrong, and the one decision that actually controls your cost.

Key Takeaways

• All FEHB plans must cover at least one GLP-1 weight-loss drug in 2026, but "covered" is not the same as "affordable."
• The same Wegovy ranges from about $420/year (BCBS Standard with Part D) to about $9,840/year (Kaiser at 50% coinsurance). A $9,420 spread for one drug.
• Ozempic and Wegovy are the same drug (semaglutide) with different FDA labels, and plans treat them differently. The weight-loss path needs a prior authorization the diabetes path often doesn't.
• A new Medicare GLP-1 Bridge (July 1, 2026) gives eligible retirees Wegovy for a flat $50/month, but that copay doesn't count toward the Part D cap.
• Open Season (November 2026) is the single biggest lever on your GLP-1 cost. Pick the plan around the drug.

"Covered" Doesn't Mean Affordable

OPM requires every FEHB plan to cover at least one GLP-1 anti-obesity drug, plus at least two oral alternatives. But plans control the part that actually hits your wallet: the tier and the cost-share. Wegovy lists around $1,643/month and Zepbound around $1,266/month at retail. What you pay depends entirely on where your plan files the drug.

BCBS FEP Basic quietly moved Wegovy from a roughly $60/month Tier 2 drug to a $600-$767/month non-preferred Tier 3 drug in 2025. Same plan, same drug, ten times the cost, with little fanfare. That's the kind of change that makes "my plan covers it" a dangerous thing to assume.

The Ozempic vs Wegovy Trap

This is the part most federal employees get wrong. Ozempic and Wegovy contain the same active ingredient (semaglutide). Mounjaro and Zepbound are both tirzepatide. The difference is the FDA label, and plans treat the labels very differently.

Drug	Ingredient	FDA use	FEHB path
Ozempic	Semaglutide	Type 2 diabetes	Diabetes formulary, usually no weight-loss PA
Wegovy	Semaglutide	Weight management	Covered, but needs a weight-loss prior authorization
Mounjaro	Tirzepatide	Type 2 diabetes	Diabetes formulary
Zepbound	Tirzepatide	Weight management	Limited; often only via formulary exception

So a fed with Type 2 diabetes can often get Ozempic with fewer hurdles than someone seeking Wegovy for weight loss, even though it's chemically the same molecule. If your goal is weight loss, the covered route is the weight-loss-labeled drug (Wegovy or Zepbound), and that means clearing a prior authorization.

That prior authorization almost always requires: a BMI of 30+ (or 27+ with a condition like Type 2 diabetes, high blood pressure, or high cholesterol), proof you're in a structured weight-management program, and, at the 6-month renewal, documented weight loss of at least 5%. Miss that 5% and you can lose coverage mid-year.

Plan-by-Plan GLP-1 Coverage (2026)

This is the comparison no other federal-employee site publishes in one place.

Plan	Wegovy	Zepbound	Cost structure	Est. monthly out-of-pocket
BCBS FEP Standard	Yes	Exception only	Tier 2 (with Part D)	~$35 with Part D; $640+ without
BCBS FEP Basic	Yes	Exception only	Tier 3 non-preferred	$600-$767
FEP Blue Focus	Yes	Yes	Tier 2 preferred	Lower preferred rate
GEHA (High/Standard/HDHP)	Yes (PA)	Exception only	Non-preferred	Higher; varies
Kaiser (all regions)	Yes	Yes	50% coinsurance	$530-$820

Estimates assume a full maintenance dose. Verify your specific drug and dose on the carrier's pricing tool, because tiers shift annually.

The $9,420 Open Season Decision

Put it in annual dollars for one person on maintenance-dose Wegovy:

Plan	Annual Wegovy cost
BCBS Standard (Tier 2, with Part D)	~$420
GEHA Standard (non-preferred)	~$2,400-$4,800
Kaiser (50% coinsurance)	~$6,360-$9,840
BCBS Basic (Tier 3)	~$7,680-$9,204
No coverage (retail)	~$19,716

The spread between the best and worst FEHB plan is roughly $9,420 a year for the same drug. That number matters more than almost any premium difference. If switching to a better-covering plan costs you $1,000-$2,000 more in premiums but saves $9,000 on the drug, you're still thousands ahead. The plan you choose in November is the decision that sets your GLP-1 cost for the whole year.

The Medicare GLP-1 Bridge for Retirees

If you're a federal retiree on Medicare, there's a new option. Starting July 1, 2026, CMS is running a demonstration called the Medicare GLP-1 Bridge that lets eligible Part D enrollees (including FEHB retirees in EGWP plans) get Wegovy, Foundayo, and the Zepbound KwikPen for a flat $50/month copay.

Eligibility is BMI 35+, or 30+ with a qualifying condition, plus a prior authorization. Compared to roughly $640/month for Wegovy without coverage, that's about $7,080 a year saved.

The catch GovExec flagged: that $50 doesn't count toward the Part D $2,100 out-of-pocket cap or your FEHB medical out-of-pocket maximum. For a retiree with lots of other drug costs, that matters, because the Bridge spending won't help you reach catastrophic protection on everything else. For most people the savings still win, but if you have very high total drug spending, model whether a standard Part D plan that covers Wegovy (and counts toward the cap) beats the Bridge. One more thing: the program expires December 31, 2027, so anyone starting on it needs a plan for 2028.

What Changes in 2027

OPM's 2027 call letter requires every FEHB and PSHB plan to cover at least one GLP-1 anti-obesity drug plus two oral alternatives. It also adds a new hurdle: intensive behavioral therapy (IBT) with a licensed human coach, before and during treatment. An AI coaching app won't satisfy it. If you're planning GLP-1 coverage for 2027, expect more paperwork before the prescription clears, so start early.

Pick the Plan Around the Drug

Premiums are only half the FEHB math when a GLP-1 is involved. Use the FEHB Premium Calculator to compare plan premiums, then layer the drug cost on top using each carrier's drug pricing tool. The plan with the slightly higher premium often wins by thousands once the GLP-1 tier is factored in. For the broader 2027 changes, see our FEHB 2027 changes guide.

Frequently Asked Questions

Does FEHB cover Ozempic for weight loss?

Most FEHB plans cover Ozempic for its FDA-approved use, Type 2 diabetes, under standard diabetes formulary rules. Ozempic is not FDA-approved for weight loss; Wegovy is, and it's the same active ingredient (semaglutide). If weight loss is the goal, the covered route is Wegovy, which requires a weight-loss prior authorization. Using a diabetes-labeled drug off-label for weight loss may not be covered.

Which FEHB plan covers Wegovy at the lowest cost in 2026?

BCBS FEP Standard paired with a Part D plan can bring Wegovy to roughly $35/month, and FEP Blue Focus places semaglutide on Tier 2 preferred. BCBS FEP Basic and GEHA moved Wegovy to non-preferred tiers, which costs far more. Kaiser uses 50% coinsurance, often the most expensive structure. Always check your plan's drug pricing tool before Open Season, because tiers change every year.

Does FEHB cover Zepbound for weight loss?

Less reliably than Wegovy in 2026. BCBS FEP Basic and Standard cover Zepbound only via a formulary exception, and GEHA requires an exception too. Kaiser covers it at specialty-tier coinsurance. The 2027 OPM mandate will require every plan to cover at least one GLP-1 anti-obesity drug, but the specific covered drug may still be plan-dependent.

What is the Medicare GLP-1 Bridge?

A CMS demonstration launching July 1, 2026 that lets eligible Medicare Part D enrollees, including federal retirees in FEHB EGWP plans, get Wegovy, Foundayo, and the Zepbound KwikPen for a flat $50/month copay. It requires BMI 35+ (or lower with qualifying conditions) and prior authorization, and it runs through December 31, 2027. The catch: the $50 doesn't count toward the Part D out-of-pocket cap.

Should I switch FEHB plans at Open Season to get cheaper GLP-1 coverage?

If you use or plan to start a GLP-1 for weight loss, usually yes, but run the full math. The gap between the best-covered plan (BCBS Standard with Part D, ~$35/month) and the worst (Kaiser at 50% coinsurance, $530-$820/month) is $6,000-$9,000 a year on the drug alone, which dwarfs most premium differences. Verify the drug's tier and copay on the carrier's pricing tool before switching.

Related Resources

• FEHB Premium Calculator: Compare plan premiums, then add the GLP-1 cost layer.
• FEHB 2027 Changes and the OPM Call Letter: The 2027 IBT mandate and what else is changing.
• FEHB Plan Evaluation Guide 2026: How to compare plans beyond premiums.

Sources: GovExec: GLP-1 options for federal retirees, CMS Medicare GLP-1 Bridge, Checkbook: FEHB weight-loss drug coverage, OPM 2027 FEHB Call Letter. Annual cost ranges are FedTools 2026 analysis of FEHB plan formularies; verify your drug's tier on your carrier's pricing tool before Open Season.